about
The impact and cost of scaling up GeneXpert MTB/RIF in South AfricaHIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions.Feasibility, yield, and cost of active tuberculosis case finding linked to a mobile HIV service in Cape Town, South Africa: a cross-sectional study.Retention in care and outpatient costs for children receiving antiretroviral therapy in Zambia: a retrospective cohort analysisEvidence for scaling up HIV treatment in sub-Saharan Africa: A call for incorporating health system constraints.Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa.Rates and cost of hospitalization before and after initiation of antiretroviral therapy in urban and rural settings in South Africa.Cost and resource use of patients on antiretroviral therapy in the urban and semiurban public sectors of South Africa.The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa.Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case.The cost effectiveness of integrated care for people living with HIV including antiretroviral treatment in a primary health care centre in Bujumbura, Burundi.Impact and costs of algorithms for the diagnosis of adults with pulmonary tuberculosis in South Africa.Cost and outcomes of paediatric antiretroviral treatment in South Africa.Good treatment outcomes among foreigners receiving antiretroviral therapy in Johannesburg, South Africa.Changing the South African national antiretroviral therapy guidelines: The role of cost modelling.The per-patient costs of HIV services in South Africa: Systematic review and application in the South African HIV Investment Case
P50
Q28484044-8ADBEF69-45D6-4AB4-86D3-7C5648FA491CQ34339471-16C1AD17-F779-4A47-9912-03A42A629840Q34373838-1055B000-A1FB-44DE-8F4B-AA9571155845Q34808183-450844F6-8303-471F-8634-64B53192CAB7Q36286256-4FB4D9AE-F68B-41A3-8CFD-7D578A2908AEQ36424212-DB42FC5D-0D51-4289-A7DE-4B357B11440BQ36763727-329B18E7-96CA-4FC7-8887-EF24DE9C9CE0Q39248598-E426C3AD-03DA-4F91-9289-C0DD5F29171AQ39559433-17DBA5E3-9FD6-4B80-90F6-E67C23F0731EQ44032580-DDF21B8A-45B2-4359-B6F1-FCD5A972F72EQ45238075-B04B5839-4647-4DF0-BAAC-3E05B691DCF0Q45991870-ED078980-3EBE-48A2-850F-FA845E741F1AQ46487268-D2AF32D4-778E-48F3-891F-41F8A5BFCAE4Q46561988-31362A0A-733D-4EA8-A884-822BCF34F5BBQ46736922-43F85E19-1B07-4593-8C04-673EB69CBE76Q64102807-CFBCCAEA-769F-4B8F-A2FF-44190D081E22
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gesine Meyer-Rath
@ast
Gesine Meyer-Rath
@en
Gesine Meyer-Rath
@es
Gesine Meyer-Rath
@nl
Gesine Meyer-Rath
@sl
type
label
Gesine Meyer-Rath
@ast
Gesine Meyer-Rath
@en
Gesine Meyer-Rath
@es
Gesine Meyer-Rath
@nl
Gesine Meyer-Rath
@sl
prefLabel
Gesine Meyer-Rath
@ast
Gesine Meyer-Rath
@en
Gesine Meyer-Rath
@es
Gesine Meyer-Rath
@nl
Gesine Meyer-Rath
@sl
P106
P21
P31
P496
0000-0003-0439-381X